"New studies are revealing how medications that act on the glucagon-like peptide-1 (GLP-1) system influence brain networks tied to nausea, thirst, and reward-driven behaviors. GLP-1 drugs include commonly used treatments such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound). These findings will be featured at Neuroscience 2025, the Society for Neuroscience's annual meeting and the largest global event for new research in brain science and health."
"Medications that work through the GLP-1 system are widely prescribed for type 2 diabetes and obesity. They imitate a natural hormone released in the digestive tract after eating and signal the brain to reduce hunger. Although these drugs are effective, up to 40% of people taking them experience side effects such as nausea and vomiting, which often lead to stopping treatment."
Medications acting on the GLP-1 system are prescribed for type 2 diabetes and obesity and mimic a digestive hormone to signal the brain to reduce hunger. These drugs are effective for weight loss but cause gastrointestinal side effects such as nausea and vomiting in up to 40% of users, often leading to treatment discontinuation. Combining low doses of tirzepatide with oxytocin produced weight loss without gastrointestinal side effects in obese rats. Nerve cells in the area postrema contribute to both weight loss and nausea responses to GLP-1 drugs in mice. Activation of GLP-1 receptors in the central amygdala engages a circuit that suppresses pleasure-driven eating.
Read at ScienceDaily
Unable to calculate read time
Collection
[
|
...
]